MAR vs PFE: Which Is the Better Buy?
Side-by-side comparison of Marriott International, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-07.
Marriott International, Inc. · Consumer Cyclical
$359.06
-45.0% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MAR |
PFE |
| Current Price |
$359.06 |
$26.33 |
| Fair Value Estimate |
$197.48 |
$33.85 |
| Upside to Fair Value |
-45.0%
|
+28.6%
|
| Market Cap |
$95.2B |
$149.8B |
| Forward P/E |
37.7x
|
19.3x
|
| EV / EBITDA |
29.5x
|
12.9x
|
| Price / Sales |
4.4x
|
2.4x
|
| Price / FCF |
29.3x
|
16.5x
|
| Revenue Growth YoY |
-71.1%
|
-1.2%
|
| Gross Margin |
6.0%
|
70.3%
|
| Operating Margin |
19.6%
|
24.7%
|
| Return on Equity |
-78.5%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.41%
|
6.06%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Marriott International operates a global fee-driven, asset-light hotel business with a portfolio of over 30 brands and a strong competitive position in the travel lodging industry. The company benefits from a durable competitive moat supported by its brand strength, extensive network, and recurring franchise and management fees. However, recent financials show significant headwinds with a 71.1% y…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
MAR |
PFE |
| Zone Low |
$148.11 |
$25.39 |
| Zone High |
$167.86 |
$28.77 |
| In Buy Zone? |
No
|
Yes
|